Physician profile

Bassel Jallad

Hematology & Oncology · Saint Louis, MO

NPI 1124282306

$1,018.51

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Daiichi Sankyo INC. $300.00 2021
Janssen Biotech, INC. $128.40 2019
Amgen INC. $94.30 2019
Novo Nordisk INC $57.03 2019
Merck Sharp & Dohme LLC $49.96 2019
Novartis Pharmaceuticals Corporation $45.36 2019
Janssen Scientific Affairs, LLC $36.79 2019
E.R. Squibb & Sons, L.L.C. $35.59 2019
Taiho Oncology, INC. $28.24 2019
Pfizer INC. $28.15 2019
Celgene Corporation $21.40 2019
Astellas Pharma US INC $20.52 2019
Genzyme Corporation $19.84 2019
Alexion Pharmaceuticals, INC. $19.64 2019
Lilly USA, LLC $18.27 2019
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Jazz Pharmaceuticals INC. $17.32 2019
Exelixis INC. $15.44 2019
Pharmacyclics LLC, An Abbvie Company $14.40 2019
Incyte Corporation $14.29 2019
Janssen Pharmaceuticals, INC $14.25 2019
Takeda Pharmaceuticals U.S.A., INC. $13.80 2019
Astrazeneca Pharmaceuticals LP $13.78 2019
Agios Pharmaceuticals, INC. $11.74 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bassel Jallad

$1,018.51

in general payments reported 2019-2025

Years
2019-2021
Top company
Daiichi Sankyo INC.

https://glasscript.com/doctor/651716/bassel-jallad

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.